Abstract
EBV-associated post-transplant lymphoproliferative disorder (PTLD) is a lift-threatening complication in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT).1, 2 The incidence of PTLD ranges from 0.2 to 22% in allo-HSCT recipients, depending on the number of risk factors.3, 4 Although the introduction of rituximab as a first-line treatment has improved outcome of PTLD, PTLD with central nervous system (CNS-PTLD) involvement still has a dismal prognosis because of low penetrance of rituximab across the blood-brain barrier.5, 6, 7 In this prospective study, we reported the successful treatment with intrathecal rituximab in CNS-PTLD who had failed to respond to the IV rituximab-based treatments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
